Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?

Bishop BM.

Am J Ther. 2015 Mar-Apr;22(2):147-58. doi: 10.1097/MJT.0b013e31828b8463. Review.

PMID:
23567794
2.

Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Mohammadpour AH, Akhlaghi F.

Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.

3.
4.

Dalcetrapib: a review of Phase II data.

Robinson JG.

Expert Opin Investig Drugs. 2010 Jun;19(6):795-805. doi: 10.1517/13543784.2010.488219. Review.

PMID:
20465364
5.

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Shinkai H.

Vasc Health Risk Manag. 2012;8:323-31. doi: 10.2147/VHRM.S25238. Epub 2012 May 15. Review.

6.

Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?

Schaefer EJ.

Curr Opin Lipidol. 2013 Jun;24(3):259-64. doi: 10.1097/MOL.0b013e3283612454. Review.

PMID:
23652567
7.

Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.

Sirtori CR.

Expert Opin Investig Drugs. 2011 Nov;20(11):1543-54. doi: 10.1517/13543784.2011.614946. Epub 2011 Oct 1. Review.

PMID:
21961529
8.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
9.

[HDL and CETP in atherogenesis].

Pöss J, Böhm M, Laufs U.

Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Review. German.

PMID:
20082258
10.

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Shinkai H.

Expert Opin Ther Pat. 2009 Sep;19(9):1229-37. doi: 10.1517/13543770903198451. Review.

PMID:
19663630
11.

Anacetrapib: hope for CETP inhibitors?

Gurfinkel R, Joy TR.

Cardiovasc Ther. 2011 Oct;29(5):327-39. doi: 10.1111/j.1755-5922.2010.00142.x. Epub 2010 Apr 9. Review.

PMID:
20406242
12.
13.

Therapeutic targets to raise HDL in patients at risk or with coronary artery disease.

Lüscher TF, von Eckardstein A, Simic B.

Curr Vasc Pharmacol. 2012 Nov;10(6):720-4. Review.

PMID:
23259565
14.

Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.

Kalgutkar AS, Frederick KS, Hatch HL, Ambler CM, Perry DA, Garigipati RS, Chang GC, Lefker BA, Clark RW, Morehouse LA, Francone O, Hu X.

Xenobiotica. 2014 Jul;44(7):591-605. doi: 10.3109/00498254.2013.874611. Epub 2013 Dec 31.

PMID:
24380613
15.

The end of the road for CETP inhibitors after torcetrapib?

Joy T, Hegele RA.

Curr Opin Cardiol. 2009 Jul;24(4):364-71. Review.

PMID:
19522058
16.

Cholesteryl ester transfer protein inhibitors: challenges and perspectives.

Filippatos TD, Klouras E, Barkas F, Elisaf M.

Expert Rev Cardiovasc Ther. 2016 Aug;14(8):953-62. doi: 10.1080/14779072.2016.1189327. Epub 2016 May 28. Review.

PMID:
27171534
17.

Future of cholesteryl ester transfer protein inhibitors.

Rader DJ, deGoma EM.

Annu Rev Med. 2014;65:385-403. doi: 10.1146/annurev-med-050311-163305. Review.

PMID:
24422575
18.

Evacetrapib.

Nicholls SJ.

Curr Cardiol Rep. 2012 Jun;14(3):245-50. doi: 10.1007/s11886-012-0252-3. Review.

PMID:
22362199
19.

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators.

Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.

20.

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Niesor EJ.

Curr Opin Lipidol. 2011 Aug;22(4):288-95. doi: 10.1097/MOL.0b013e3283475e00. Review.

PMID:
21587074

Supplemental Content

Support Center